Compounds > 1-methyl-4-phenylpyridinium
Page last updated: 2024-08-23

1-methyl-4-phenylpyridinium and Astrocytosis

1-methyl-4-phenylpyridinium has been researched along with Astrocytosis in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cory-Slechta, DA; Di Monte, DA; Langston, JW; Manning-Bog, AB; McCormack, AL; Thiffault, C; Thiruchelvam, M1
Albers, DS; Beal, MF; Browne, SE; Chirichigno, JW; Gregorio, J; Joh, TH; Lorenzl, S; Shimizu, Y; Shin, DH; Sugama, S; Yang, L1
Block, M; Hong, JS; Miller, DS; Pei, Z; Reece, JM; Wang, T; Wilson, B; Zhang, W1
Cai, DF; Chen, YP; Gao, JP; Li, WW; Sun, S1
Aoyama, S; Ikeda, K; Kurokawa, M; Kuwana, Y1

Other Studies

5 other study(ies) available for 1-methyl-4-phenylpyridinium and Astrocytosis

ArticleYear
Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat.
    Neurobiology of disease, 2002, Volume: 10, Issue:2

    Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Dopamine; Environmental Exposure; gamma-Aminobutyric Acid; Gliosis; Herbicides; Homovanillic Acid; Humans; Injections, Intraperitoneal; Male; Mesencephalon; Mice; Mice, Inbred C57BL; Nerve Degeneration; Nerve Tissue Proteins; Neurons; Paraquat; Parkinson Disease; Parkinson Disease, Secondary; Parkinsonian Disorders; Risk Factors; Substantia Nigra; Tyrosine 3-Monooxygenase

2002
Minocycline enhances MPTP toxicity to dopaminergic neurons.
    Journal of neuroscience research, 2003, Oct-15, Volume: 74, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Dopamine; Dose-Response Relationship, Drug; Doxycycline; Drug Administration Schedule; Drug Synergism; Gliosis; Male; Mice; Mice, Inbred C57BL; Microglia; Minocycline; Neostriatum; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Substantia Nigra; Synaptic Vesicles; Tetracycline

2003
Reactive microgliosis participates in MPP+-induced dopaminergic neurodegeneration: role of 67 kDa laminin receptor.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2006, Volume: 20, Issue:7

    Topics: 1-Methyl-4-phenylpyridinium; Animals; Antibodies; Cells, Cultured; Gliosis; Laminin; Mice; Microglia; Neurons; Oligopeptides; Parkinson Disease; Receptors, Laminin; Superoxides

2006
Triptolide protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats: implication for immunosuppressive therapy in Parkinson's disease.
    Neuroscience bulletin, 2008, Volume: 24, Issue:3

    Topics: 1-Methyl-4-phenylpyridinium; Animals; Biomarkers; CD11b Antigen; Cell Count; Cell Survival; Disability Evaluation; Diterpenes; Dopamine; Encephalitis; Epoxy Compounds; Gliosis; Herbicides; Immunosuppression Therapy; Immunosuppressive Agents; Male; Microglia; Neurons; Parkinsonian Disorders; Phenanthrenes; Rats; Rats, Sprague-Dawley; Substantia Nigra; Treatment Outcome; Tyrosine 3-Monooxygenase

2008
Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease.
    Journal of neurochemistry, 2002, Volume: 80, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Antineoplastic Agents; Disease Models, Animal; Dopamine; Dopamine Agents; Gliosis; Herbicides; Male; Nerve Degeneration; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; PC12 Cells; Purinergic P1 Receptor Antagonists; Purines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Sympatholytics; Tritium

2002